CA0717051076 - Common Stock
BAUSCH + LOMB CORP
NYSE:BLCO (6/10/2024, 7:04:01 PM)
After market: 15.01 0 (0%)15.01
-0.31 (-2.02%)
Bausch + Lomb Corp. develops, manufactures, and markets eye health products. The company is headquartered in Vaughan, Ontario and currently employs 12,900 full-time employees. The company went IPO on 2022-05-06. The Company’s Vision Care segment includes both a contact lens business and a consumer eye care business that consists of contact lens care products, over the counter (OTC) eye drops and eye vitamins. The Company’s Ophthalmic Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Its Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. The Company’s brands include PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, and many more.
BAUSCH + LOMB CORP
520 Applewood Crescent
Vaughan ONTARIO
P: 19082552864
Employees: 12900
Website: https://ir.bausch.com/
BLCO stock results show that Bausch & Lomb met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.
Here you can normally see the latest stock twits on BLCO, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: